Learn more about other ways that you can support the global effort to end AIDS.
The U.S. Department of Health and Human Services (HHS) is the United States Government’s principal agency for protecting the health of all Americans. The Department of Health and Human Services’ (HHS) Office of the Assistant Secretary for Health and Office of the Assistant Secretary for Public Affairs have spearheaded the creation of AIDS.gov, but the project is truly a Federal effort. The design and development team includes representatives from HHS and other Federal government agencies and agency-specific subject-matter experts and Web managers. HHS is the managing sponsor of AIDS.gov.
AIDSinfo, a project of the U.S. Department of Health and Human Services, offers the latest federally approved information on HIV/AIDS clinical research, treatment and prevention, and medical practice guidelines for people living with HIV/AIDS, their families and friends, health care providers, and researchers. AIDSinfo serves as the main dissemination point for federally approved HIV treatment and prevention guidelines, and provides information on clinical research trials for people infected with HIV. All of the information provided by AIDSinfo is from federal government agencies, including the National Institutes of Health, the Centers for Disease Control and Prevention, and the Health Resources and Services Administration, among others.
DAIDS is a Division within the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH). DAIDS was formed in 1986 to develop and implement the national research agenda to address the HIV/AIDS epidemic. Specifically, the mission of DAIDS is to help ensure an end to the HIV/AIDS epidemic by increasing basic knowledge of the pathogenesis and transmission of HIV, supporting the development of therapies for HIV infection and its complications and co-infections, and supporting the development of vaccines and other prevention strategies.
To learn about clinical research sites in your area, visit the link above.
The HPTN is a worldwide collaborative clinical trials network that develops and tests the safety and efficacy of primarily non-vaccine interventions designed to prevent the acquisition and transmission of HIV. The HPTN is funded by the Division of AIDS (DAIDS) of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), the HPTN carries out its mission through a strong network of expert scientists and investigators from both international and U.S. institutions and partnered with a leadership group comprised of three U.S.-based institutions. The HPTN research agenda is focused primarily on the use of antiretroviral therapy for HIV Prevention; treatment and prevention of sexually transmitted infections; treatment of substance abuse, particularly injection drug use; behavioral risk reduction interventions and structural interventions to reduce HIV transmission and acquisition.
The HVTN is an international organization of scientists and educators who have come together to develop a safe and effective preventive HIV vaccine. It facilitates the production and testing of vaccines against HIV/AIDS and conducts all phases of clinical evaluation, from testing experimental vaccines for safety to testing the effectiveness of vaccines in preventing HIV. The HVTN was created in 1999 by the Division of AIDS (DAIDS) of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).
IAVI is a global nonprofit organization working to speed the search for a vaccine to prevent HIV and AIDS. IAVI also advocates for a vaccine to be a global priority and works to ensure that a future vaccine will be accessible to all who need it.
MHRP is a leader in international efforts to combat HIV. It strives to protect U.S. troops from HIV infection and to reduce the global impact of the disease. While its primary focus is developing a globally effective HIV vaccine, the program also provides prevention, care, and treatment. MHRP’s multi-dimensional approach combines strong vaccine science, the careful development of research sites, and partnerships with key research institutions in the U.S. and host countries.
Established in 2006 by the National Institute of Allergy and Infection Diseases (NIAID), the MTN brings together international investigators and community and industry partners who are devoted to reducing the sexual transmission of HIV through the development and evaluation of products applied topically or administered orally, working within a unique infrastructure specifically designed to facilitate research required to support licensure of these products for widespread use. MTN's research portfolio includes trials that are focused on assessing antiretroviral (ARV)-based microbicides and include studies designed to evaluate microbicides along with other promising HIV prevention approaches, such as the daily use of ARVs as pre-exposure prophylaxis (PrEP).
USAID provides support to the International AIDS Vaccine Initiative (IAVI), a nongovernmental organization, to accelerate the development of an effective vaccine for HIV prevention. USAID funds are used to support Vaccine Development Partnerships focused on advancing HIV vaccine candidates to clinical trials. Among the activities supported are site development and community preparations for HIV vaccine efficacy trials in developing countries and public policy research to accelerate and support HIV vaccine research/development and future access. Vaccine clinical trial centers have been established in Kenya, Uganda, Rwanda, Zambia, South Africa, and India.
The VRC conducts preventive HIV vaccine research and development at a facility located on the campus of the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). The VRC’s research is funded by the U.S. Department of Health and Human Services.